About this book:

"Laboratory Corp. of America Holding: The Story of An American Company" chronicles the remarkable evolution of Labcorp from its humble beginnings in a Burlington, North Carolina hospital basement to its current stature as a global leader in clinical diagnostics and drug development. Founded by the visionary Powell family as Biomedical Laboratories in 1969, the company revolutionized diagnostic testing by prioritizing speed and accuracy, an audacious goal in an era of week-long turnaround times. This foundational commitment to innovation propelled early growth, marked by strategic acquisitions like American Biomedical Corporation, which expanded both its geographical reach and technological capabilities. The narrative explores key mergers, notably with National Health Laboratories, and significant corporate transformations under the ownership of Hoffman-La Roche, ultimately leading to the birth of Labcorp in 1995 as a publicly traded powerhouse.

The book details Labcorp's strategic expansion in the late 20th and early 21st centuries, illustrating how it diversified its service offerings far beyond routine blood work. Through a series of targeted acquisitions, the company became a pioneer in specialized diagnostics, including advanced genomic and oncology testing, infectious disease diagnostics, and anatomical pathology. A defining moment in its trajectory was the 2015 acquisition of Covance, a global contract research organization, which fundamentally transformed Labcorp into a comprehensive life sciences company with a significant footprint in preclinical research and clinical trial management. The narrative also highlights Labcorp's critical role in public health, from responding to outbreaks like H1N1 and Zika to its monumental contributions during the COVID-19 pandemic, where it rapidly developed and scaled testing, including pioneering at-home collection kits.

Looking forward, the book examines Labcorp's relentless embrace of digital healthcare and new technologies, from the direct-to-consumer Labcorp OnDemand platform to the integration of AI and machine learning in pathology and drug development. It delves into the company's robust business model, balancing its vast Diagnostics Laboratories segment with its Biopharma Laboratory Services, which continue to support the majority of new FDA-approved drugs. The book concludes by emphasizing Labcorp's strong financial performance, its competitive strategies in a dynamic healthcare landscape, and its deep commitment to corporate social responsibility and sustainability, solidifying its position as an indispensable force in improving global health and lives.

What You'll Find Inside:

• Chronicles Labcorp's journey from a small regional laboratory in 1969 to a global powerhouse in clinical diagnostics and drug development, highlighting key mergers and acquisitions.
• Explores Labcorp's pioneering role in diagnostic innovation, including early adoption of PCR technology, advanced genomic testing, and the development of at-home collection kits.
• Details the transformative Covance acquisition, which expanded Labcorp's services into preclinical research, clinical trial management, and central laboratory services for pharmaceutical companies.
• Showcases Labcorp's critical contributions to public health challenges, including its rapid response during the COVID-19 pandemic and its role in widespread testing and vaccine research support.
• Highlights Labcorp's embrace of digital healthcare, including direct-to-consumer testing, AI-powered pathology, integrated EHR solutions, and its significant impact on precision medicine.

Who's It For:

This book is ideal for healthcare professionals, medical students, and researchers interested in the evolution of diagnostic testing and drug development. It also appeals to business students, investors, and industry analysts seeking a comprehensive understanding of a major life sciences company's growth strategy, financial performance, and market position. Anyone curious about the interplay between scientific innovation, corporate strategy, and public health will find this a valuable read.